Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases

Current Opinion in Pharmacology

Volumn 37, Issue , 2017, Pages 80-86

  Malhi, Harmeet ^a   Camilleri, Michael ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BILE ACID; CHENODEOXYCHOLIC ACID; COLESEVELAM; COLESTYRAMINE; DIGESTIVE TRACT AGENT; FARNESOID X RECEPTOR; FEXARAMINE; G PROTEIN COUPLED BILE ACID RECEPTOR 1; GSK 2330672; HYDROXYPROPYLCELLULOSE; MARALIXIBAT; NGM 282; OBETICHOLIC ACID; PROTEIN INHIBITOR; RECEPTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; G PROTEIN COUPLED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

BILE ACID DIARRHEA; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GASTROINTESTINAL DISEASE; HUMAN; ILEITIS; LIVER DISEASE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PRURITUS; REVIEW; SIGNAL TRANSDUCTION; SPOROGENESIS; TISSUE DISTRIBUTION; ANIMAL; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85032676174     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2017.09.008     Document Type: Review

References (44)

1. Bunnett, N.W., Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract. J Physiol 592 (2014), 2943–2950.
2. Wingate, D.L., Krag, E., Mekhjian, H.S., Phillips, S.F., Relationships between ion and water movement in the human jejunum, ileum and colon during perfusion with bile acids. Clin Sci Mol Med 45 (1973), 593–606.
3. Kirwan, W.O., Smith, A.N., Mitchell, W.D., et al. Bile acids and colonic motility in the rabbit and the human. Gut 16 (1975), 894–902.
4. Bampton, P.A., Dinning, P.G., Kennedy, M.L., et al. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol 282 (2002), G443–G449.
5. Brighton, C.A., Rievaj, J., Kuhre, R.E., et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology 156 (2015), 3961–3970.
6. Bazzoli, F., Malavolti, M., Petronelli, A., Barbara, L., Roda, E., Treatment of constipation with chenodeoxycholic acid. J Int Med Res 11 (1983), 120–123.
7. Chadwick, V.S., Gaginella, T.S., Carlson, G.L., Debongnie, J.C., Phillips, S.F., Hofmann, A.F., Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 94 (1979), 661–674.
8. Kelly, O.B., Mroz, M.S., Ward, J.B., Colliva, C., Scharl, M., Pellicciari, R., Gilmer, J.F., Fallon, P.G., Hofmann, A.F., Roda, A., Murray, F.E., Keely, S.J., Ursodeoxycholic acid attenuates colonic epithelial secretory function. J Physiol 591 (2013), 2307–2318.
9. − exchange activity in Caco2 cells. Dig Dis Sci 52 (2007), 1270–1278.
10. − secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol 305 (2013), C447–C456.
11. Peregrin, A.T., Ahlman, H., Jodal, M., Lundgren, O., Involvement of serotonin and calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin. Br J Pharmacol 127 (1999), 887–894.
12. Poole, D.P., Godfrey, C., Cattaruzza, F., Cottrell, G.S., Kirkland, J.G., Pelayo, J.C., Bunnett, N.W., Corvera, C.U., Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 22 (2010), 814–825.
13. Alemi, F., Poole, D.P., Chiu, J., Schoonjans, K., Cattaruzza, F., Grider, J.R., Bunnett, N.W., Corvera, C.U., The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144 (2013), 145–154.
14. Vijayvargiya, P., Busciglio, I., Burton, D., Donato, L., Lueke, A., Camilleri, M., Bile acid deficiency in subgroup of irritable bowel syndrome with constipation based on serum and fecal biomarkers. Clin Gastroenterol Hepatol, 2017, 10.1016/j.cgh.2017.06.039 pii: S1542-3565(17)30786-3 [Epub ahead of print].
15. Rao, A.S., Wong, B., Camilleri, M., Odunsi-Shiyanbade, S.T., McKinzie, S., Ryks, M., Burton, D., Carlson, P., Lamsam, J., Singh, R., Zinsmeister, A.R., Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139 (2010), 1549–1558.
16. Wong, B.S., Camilleri, M., McKinzie, S., Burton, D., Graffner, H., Zinsmeister, A.R., Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 106 (2011), 2154–2164.
17. Chey, W.D., Camilleri, M., Chang, L., Rikner, L., Graffner, H., A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 106 (2011), 1803–1812.
18. Nakajima, A., Seki, M., Taniguchi, S., Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. J Gastroenterol, 2017, 10.1007/s00535-017-1383-5 [Epub ahead of print].
19. Oduyebo, I., Nelson, A.D., Khemani, D., et al. NGM282, variant of FGF19, is a gastric and colonic prokinetic and stimulates bowel function in patients with functional constipation: phase 1B, two-dose, placebo-controlled study. Gastroenterology, 152, 2017, S1315.
20. Valentin, N., Camilleri, M., Altayar, O., Vijayvargiya, P., Acosta, A., Nelson, A.D., Murad, M.H., Biomarkers for bile acid diarrhea in functional bowel disorder with diarrhea: a systematic review and meta-analysis. Gut 65 (2016), 1951–1959.
21. Fernández-Bañares, F., Rosinach, M., Piqueras, M., et al. Randomised clinical trial: cholestyramine vs. hydroxypropyl cellulose in patients with functional chronic watery diarrhoea. Aliment Pharmacol Ther 41 (2015), 1132–1140.
22. Wilcox, C., Turner, J., Green, J., Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther 39 (2014), 923–939.
23. Bajor, A., Törnblom, H., Rudling, M., et al. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 64 (2015), 84–92.
24. Camilleri, M., Acosta, A., Busciglio, I., et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 41 (2015), 438–448.
25. Odunsi-Shiyanbade, S.T., Camilleri, M., McKinzie, S., et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 8 (2010), 159–165.
26. Lin, S., Sanders, D.S., Gleeson, J.T., et al. Long-term outcomes in patients diagnosed with bile-acid diarrhoea. Eur J Gastroenterol Hepatol 28 (2016), 240–245.
27. Walters, J.R., Johnston, I.M., Nolan, J.D., et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 41 (2015), 54–64.
28. Weingarden, A.R., Dosa, P.I., DeWinter, E., et al. Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control Clostridium difficile germination and growth. PLOS ONE, 11, 2016, e0147210.
29. Weingarden, A.R., Chen, C., Zhang, N., et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol 50 (2016), 624–630.
30. Staley, C., Kelly, C.R., Brandt, L.J., et al. Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. MBio, 2016, 7 pii: e01965-16.
31. Chávez-Talavera, O., Tailleux, A., Lefebvre, P., et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152 (2017), 1679–1694 e3.
32. Nevens, F., Andreone, P., Mazzella, G., et al. A placebo-controlled trial of obeticholic acid in primary biliary dholangitis. N Engl J Med 375 (2016), 631–643.
33. Kuiper, E.M., Hansen, B.E., de Vries, R.A., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136 (2009), 1281–1287.
34. Hegade, V.S., Kendrick, S.F., Dobbins, R.L., et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389 (2017), 1114–1123.
35. Mayo, M.J., Wigg, A.J., Roberts, S.K., et al. NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology 62 (2015), 263A–264A.
36. − output. Hepatology 54 (2011), 1303–1312.
37. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., Dasarathy, S., Diehl, A.M., Hameed, B., Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
38. Harrison, S.A., Abdelmalek, M.F., TroRer, J.F., et al. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. Presented at The International Liver Congress™ Amsterdam, Netherlands, April 22, 2017.
39. Jiang, C., Xie, C., Li, F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125 (2015), 386–402.
40. Rao, A., Kosters, A., Mells, J.E., et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med, 8, 2016, 357ra122.
41. Fang, S., Suh, J.M., Reilly, S.M., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21 (2015), 159–165.
42. Alemi, F., Kwon, E., Poole, D.P., et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 123 (2013), 1513–1530.
43. Beuers, U., Kremer, A.E., Bolier, R., et al. Pruritus in cholestasis: facts and fiction. Hepatology 60 (2014), 399–407.
44. Hirschfield, G.M., Mason, A., Luketic, V., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148 (2015), 751–761.